The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTNEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Same-day shipping now live from the US West Coast · order by 2:30 PM PT weekdays, 12:00 PM PT Saturday →NEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
Disguised Alpha Β· CBL-514 Research

CBL-514 Phase 3: SUPREME-01 and SUPREME-02

Quick answer

As of this November 11, 2026 review, Caliway reports that both SUPREME-01 and SUPREME-02 are advancing in its pivotal CBL-514 program. A trial starting enrollment does not mean its outcomes are known or the candidate has marketing approval.

Disguised Alpha Β· November 11, 2026 Β· Sources reviewed November 11, 2026

The verified development update

Caliway’s October 29 announcement reports that SUPREME-02, also called CBL-0302, began enrollment alongside the ongoing SUPREME-01 program. The sponsor describes a randomized, double-blind, placebo-controlled study of abdominal subcutaneous fat reduction, with approximately 320 participants planned for SUPREME-02.[1]

The word β€œplanned” belongs with the enrollment figure. Target enrollment is a design feature, while actual enrollment is an observed count. A research timeline should keep those separate.

Milestones have different meanings

MilestoneWhat it establishes
Permission to proceedThe study may move forward under its authorization
Enrollment beginsRecruitment activity has started
Primary completionCollection for the primary endpoint reaches its defined completion
Results reportedData and analyses can be evaluated
Marketing decisionA separate regulatory decision has been made

The FDA’s IND explanation describes the framework for investigational studies; it is distinct from a marketing application.[2]

How to follow the program without overstating it

For each update, retain the trial identifier, publication date, current status and the source’s exact distinction between actual and anticipated events. Cross-check the registry when available. If a press release and a registry differ, record the discrepancy and their update dates rather than choosing the more optimistic version.

Future result dates are forecasts. Do not turn them into guaranteed release dates in evergreen copy. Likewise, a favorable earlier-phase result is a reason to study the question further, not the result of the upcoming trial.

This article is a dated development reference. It does not predict approval, market availability or a clinical outcome from a separately supplied research product.

Frequently asked questions

Does pivotal mean approved?

No. It describes the intended role of a study in development; approval is a separate decision.

Are enrollment targets final participant counts?

No. Planned enrollment and the number actually enrolled must be reported separately.

CBL-514 product and documentation

Review the current format and pack choices, then match the supplied lot to its documentation. No batch-specific identity, purity or content result is asserted in this article.

Sources

  1. Caliway, October 29, 2026: SUPREME-02 enrollment update
  2. FDA: Investigational New Drug applications
  3. ClinicalTrials.gov: reading a study record

Publisher disclosure: Disguised Alpha sells the research material linked here. This supplier-published article provides research education and editorial interpretation; it is not an independent clinical review. Literature findings do not establish the identity or clinical performance of DA material.

Laboratory research only. Not for human or veterinary use. No affiliation with Caliway is claimed.

βœ“
Loading...
25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop